Benralizumab

Drug Profile

Benralizumab

Alternative Names: BIW-8405; BIW-8405-IL-5R; KHK 4563; MEDI-563

Latest Information Update: 10 Jul 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer AstraZeneca; Kyowa Hakko; Kyowa Hakko Kirin; MedImmune; National Jewish Medical and Research Center
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Asthma
  • Phase III Chronic obstructive pulmonary disease
  • Phase II Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis

Most Recent Events

  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory application for Chronic obstructive pulmonary disease in Japan in 2019 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Asthma in China in 2020 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 EMA and PMDA accepts regulatory filings for barnelizumab for Asthma for review in the EU and Japan respectively (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top